carlsmed.com - רווח לפני ניכוי ריבית, מסים, בלאי ופחת CARL

Carlsmed Inc demonstrates high stability due to its FDA "breakthrough device" status and physician loyalty. Historical EBITDA_Co data on this GURU.Markets platform chart confirms a trend where the value has stabilized at 0.00. Growth is driven by AI-based 3D-printed titanium vertebrae and precision JIT logistics, which minimize inventory to enhance profitability.

This metric measures real cash flow from core operations, excluding depreciation and other non-cash charges to assess the true operational efficiency of the business. By analyzing the volume of the operating cash result, an investor can track the sustainability of sales scaling and surgeon training, which is critically important for the startup Carlsmed Inc (CARL) as it develops AI implants without relying on external M&A deals.